Please provide your email address to receive an email when new articles are posted on . 6-minute walk distances were shorter among patients with chronic thromboembolic pulmonary hypertension and low ...
Hosted on MSN
New pulmonary arterial hypertension treatment offers hope for patients in advanced stage of disease
A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Johnson & Johnson JNJ announced that it is stopping a phase III study called MACiTEPH, evaluating its pulmonary arterial hypertension (PAH) drug, macitentan (75 mg) in patients with chronic ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
CTEPH's early symptoms can be easily confused with many other diseases. Many people with CTEPH do not have any symptoms for a long time. fatigue, chest pain, and shortness of breath (especially during ...
Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results